Eli Lilly will buy Kelonia Therapeutics, a developer of an in vivo CAR-T cancer therapy, for up to $7 billion — paying $3.25bn on closing with the remainder tied to clinical, regulatory and commercial milestones. The companies expect the deal to close in the second half of 2026.

Deal terms Eli Lilly said it will acquire Kelonia Therapeutics in a transaction that could total as much as $7 billion. Lilly will pay $3.25 billion on closing and the remainder will come as milestone payments tied to clinical, regulatory and commercial objectives. The acquisition is expected to close in the second half of 2026. The structure — a sizable upfront payment followed by contingent consideration — places much of the price on Kelonia hitting future development and sales targets. That reflects the early-stage nature of Kelonia's programmes and the wider volatility in biopharma valuations where outcomes hinge on trial results and approvals. While the headline number echoes recent large cell-therapy deals elsewhere in the sector, the use of milestones limits Lilly's immediate cash exposure and ties additional payouts to measurable progress. What Kelonia's technology does Kelonia is developing an in vivo CAR-T approach designed to reprogram a patient's T-cells inside the body so they attack cancer. Traditional CAR-T therapies are manufactured ex vivo: doctors collect a patient's cells, engineers edit them in a laboratory, and clinicians infuse the altered cells back into the patient. That process can take weeks and often requires chemotherapy-based preconditioning. Jacob Van Naarden, president of Lilly oncology and head of corporate business development, described Kelonia's candidate as an "intravenously delivered therapy, one time." He said it targets a patient's T-cells directly and doesn't require preconditioning. The promise is logistical simplicity. If an in vivo approach proves safe and effective at scale, treatment could be delivered more widely than current ex vivo CAR-Ts, which remain largely confined to specialist and academic centres with the required manufacturing and clinical expertise. Why Lilly is paying up Lilly's purchase is part of a sustained push to broaden its pipeline beyond its high-profile incretin medicines for diabetes and weight loss. Van Naarden said Lilly intends to use Kelonia's platform in haematology and, potentially, for solid tumours. "Right now, Lilly is thought of as a weight loss company, and that's a very large part of our business," Van Naarden said. "But over time, the goal, very intentionally, is to use the financial strength that the incretin and the weight loss business is providing us to help diversify the business into the other therapeutic areas even more so." The acquisition follows several deals by Lilly this year, including purchases of companies working on sleep disorders and cell therapy technologies. Those transactions have varied in size and stage, signalling a strategy of buying capabilities across development stages rather than only late-stage assets. Analysts and investors generally view such bolt-on deals as a way for cash-rich drugmakers to refill pipelines after a period of heavy sales concentration in one therapeutic class. For Lilly, adding a potential in vivo CAR-T platform would mark a clear step into cell therapy and immuno-oncology — areas with fast-rising clinical and commercial interest. Market context and recent comparators Market participants have been rapidly valuing CAR-T assets. Johnson & Johnson's CAR-T for multiple myeloma, Carvykti, generated $1.89 billion in sales last year, showing the commercial potential if a therapy reaches the market.

Related Articles

The deal signals Lilly's push to diversify beyond its lucrative incretin products and move more decisively into cell therapy and immuno-oncology.

This article was created with AI assistance.